What patients should know In late 2023, the FDA placed 19 commonly used peptides on its Category 2 list, which significantly restricted compounding pharmacies from preparing them. The agency cited potential safety concerns, although many clinicians and compounding pharmacy organizations challenged the decision and argued that the restrictions were broader than the available evidence supported.…